Treatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
CONTEXT: Combined infusion of levothyroxine plus liothyronine, as opposed to levothyroxine alone, is the only way of restoring the concentrations of circulating TSH, T4, and T3 as well as those of both T4 and T3 in all tissues of thyroidectomized rats. Considering the substantial differences in thyroid hormone secretion, transport, and metabolism between rats and humans, whether or not combined levothyroxine plus liothyronine replacement therapy has advantages over treatment with levothyroxine alone in hypothyroid patients is still questioned. EVIDENCE ACQUISITION: We conducted a systematic review of all the published controlled studies comparing treatment with levothyroxine alone with combinations of levothyroxine plus liothyronine in hypothyroid patients, identified through the Entrez-PubMed search engine. EVIDENCE SYNTHESIS: Nine controlled clinical trials were identified that compared treatment with levothyroxine alone and treatment with combinations of levothyroxine plus liothyronine and included a sufficient number of adult hypothyroid patients to yield meaningful results. In only one study did the combined therapy appear to have beneficial effects on the mood, quality of life, and psychometric performance of the patients over levothyroxine alone. These results have not been confirmed by later studies using either T3 substitution protocols or approaches with fixed combinations of levothyroxine plus liothyronine, including those based on the physiological proportion in which T3 and T4 are secreted by the human thyroid. However, in some of these studies the patients preferred levothyroxine plus liothyronine combinations, for reasons not explained by changes in the psychological and psychometric tests employed. Yet patients' preference should be balanced against the possibility of adverse events resulting from the addition of liothyronine to levothyroxine, even in the small doses used in these studies. CONCLUSIONS: Until clear advantages of levothyroxine plus liothyronine are demonstrated, the administration of levothyroxine alone should remain the treatment of choice for replacement therapy of hypothyroidism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systematic reviews and metaanalyses of 18 trials of combination levothyroxine-liothyronine replacement found no clear benefit over levothyroxine monotherapy.12,13”
From Hypothyroidism (2024) · cites this paper as [13]
In the citing paper
“Furthermore, four systematic reviews and metaanalyses 12,13,180,181 of these trials found no clear benefit of combination levothyroxineliothyronine therapy over levothyroxine monotherapy in terms of mood, healthrelated quality of life, or cognitive function.”
From Hypothyroidism (2024) · cites this paper as [13]
In the citing paper
“This combined therapy aims to more closely mimic the natural secretion of the thyroid gland, potentially restoring physiological levels of T3 and T4 across various tissues [28].”
In the citing paper
“This may constitute a bias, as the benefit of combination therapy in one trial was observed only in the thyroid cancer patients and not in patients with autoimmune thyroiditis [48,49] .”
From 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism (2012) · cites this paper as [49]
In the citing paper
“Indeed, serum free T4 to free T3 ratios in patients randomized to receive L-T4 monotherapy range from 4.0 to 5.5 ( table 3 ), higher than the value of 3.3 observed in healthy controls [49] .”
From 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism (2012) · cites this paper as [49]
Citations
Cites
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Ingbar, S. H. (1965) · Archives of Internal Medicine · doi:10.1001/archinte.1965.03870060154035 · Cited by 1,743
Baskin, H. J., Cobin, R. H., Duick, D. S., Gharib, H., Guttler, R. B., Kaplan, M. M., Segal, R. L., Garber, J. R., Hamilton Jr, C. R., Handelsman, Y., et al. (2002) · Endocrine Practice · doi:10.4158/1934-2403-8.6.457 · Cited by 673
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 2×
“(30, 32) was greeted with considerable interest not only for scientific reasons but also for hypothyroid patients; combined levothyroxine plus liothyronine replacement was considered the answer to the relatively frequent complaint (35) of the persistence, with levothyroxine alone, of hypothyroid symptoms despite norma…”
BackgroundBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 7×
“(30, 32), it would appear that T3 substitution has a minor role, if any, in thyroid replacement therapy (14, 31, 41).”
BackgroundMethodResultInfluentialAdvances in Our Understanding of Thyroid Hormone Action at the Cellular Level*
OPPENHEIMER, J. H., SCHWARTZ, H. L., MARIASH, C. N., KINLAW, W. B., WONG, N. C. W., & FREAKE, H. C. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-3-288 · Cited by 476
Bianco, A. C. (2002) · Endocrine Reviews · doi:10.1210/er.23.1.38 · Cited by 423
Hennemann, G., Docter, R., Friesema, E. C. H., de Jong, M., Krenning, E. P., & Visser, T. J. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.4.0435 · Cited by 394
Fish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703263161302 · Cited by 353
Escobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118353 · Cited by 287
Self-citation
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“(525) also concluded that data on benefits of combination treatment on psychological outcomes were heterogeneous and not reproducible, and that the treatment preference for combination treatment was not explained based on results of psychologic or psychometric tests.”
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
“Why do some patients prefer combination therapy to Lthyroxine monotherapy (133)? Some insight into the latter question may be gained from a large-scale study of L-thyroxine and L-triiodothyronine combination therapy in which different responses were observed in patients with different genetic subtypes of type 2 deiodi…”
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
“…combination therapy (132), have re-ad-dressed the benefits of synthetic L-thyroxine and L-triio-dothyronine combination therapy but have largely failed to confirm an advantage of this approach to improve cognitive or mood outcomes in hypothyroid individuals treated with L-thyroxine alone (133,134).”
The Thyroid‐Brain Interaction in Thyroid Disorders and Mood Disorders
Bauer, M., Goetz, T., Glenn, T., & Whybrow, P. C. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01774.x · Cited by 438
Metadata
- Authors
- Escobar-Morreale, H. F., Botella-Carretero, J. I., del Rey, F. E., & de Escobar, G. M.
- Affiliations
- Hospital Universitario Ramón y Cajal (ES)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-08
- Volume
- 90
- Issue
- 8
- Pages
- 4946-4954
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2081588773
- Cited by
- 160
- References
- 49
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 6 · 2018: 10 · 2017: 4 · 2016: 9 · 2015: 8 · 2014: 8 · 2013: 5 · 2012: 12
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Funders
- Comunidad de Madrid
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- hypothyroidism, levothyroxine, liothyronine, T4/T3 ratio, thyroid hormone replacement, quality of life, mood, psychometric performance, patient preferences, adverse events
- MeSH terms
- Drug Therapy, Combination, Humans, Hypothyroidism, Thyroxine, Triiodothyronine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.